Company Overview of Abgentis Limited
Abgentis Limited develops IV/oral antibacterial products to treat acute and chronic, life-threatening and drug-resistant infections. It focuses on re-engineering Abgentis, a previously marketed antibacterial by deploying a unique insight into the structure-activity relationships, microbiology, pharmacology, and efficacy of antibacterial DNA supercoiling inhibitors. The company was incorporated in 2012 and is based in Abingdon, United Kingdom.
123 Alexander Close
Abingdon, OX14 1XD
Founded in 2012
44 1235 532 481
Key Executives for Abgentis Limited
Abgentis Limited Key Developments
Similar Private Companies By Industry
|Achilles Therapeutics Ltd.||Europe|
|ADC Biotechnology Ltd||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Abgentis Limited, please visit www.abgentis.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.